EPHA5, EPH receptor A5, 2044

N. diseases: 61; N. variants: 9
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.400 GeneticVariation disease CLINVAR Somatic mutations of the protein kinase gene family in human lung cancer. 16140923 2005
CUI: C0152013
Disease: Adenocarcinoma of lung (disorder)
Adenocarcinoma of lung (disorder) 		0.400 GeneticVariation disease UNIPROT
CUI: C0149782
Disease: Squamous cell carcinoma of lung
Squamous cell carcinoma of lung 		0.300 GeneticVariation disease UNIPROT
CUI: C0345958
Disease: Large cell carcinoma of lung
Large cell carcinoma of lung 		0.300 GeneticVariation disease UNIPROT
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.110 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.110 Biomarker disease BEFREE The expression profile and the role of EphA5 in colorectal carcinoma have not been well investigated till now. 27651378 2017
CUI: C0021704
Disease: Intelligence
Intelligence 		0.100 GeneticVariation phenotype GWASCAT Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. 31374203 2019
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.100 GeneticVariation disease GWASCAT Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. 31374203 2019
CUI: C1314691
Disease: Age at menarche
Age at menarche 		0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0007102
Disease: Malignant tumor of colon
Malignant tumor of colon 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0009404
Disease: Colorectal Neoplasms
Colorectal Neoplasms 		0.100 GeneticVariation group GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0037274
Disease: Dermatologic disorders
Dermatologic disorders 		0.100 GeneticVariation group GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0346629
Disease: Malignant neoplasm of large intestine
Malignant neoplasm of large intestine 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0596887
Disease: mathematical ability
mathematical ability 		0.100 GeneticVariation phenotype GWASCAT Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. 30038396 2018
CUI: C1319315
Disease: Adenocarcinoma of large intestine
Adenocarcinoma of large intestine 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C1837315
Disease: COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C2675481
Disease: COLORECTAL CANCER, SUSCEPTIBILITY TO, 10
COLORECTAL CANCER, SUSCEPTIBILITY TO, 10 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C2677123
Disease: COLORECTAL CANCER, SUSCEPTIBILITY TO, 3
COLORECTAL CANCER, SUSCEPTIBILITY TO, 3 		0.100 GeneticVariation phenotype GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C3554460
Disease: COLORECTAL CANCER, SUSCEPTIBILITY TO, 12
COLORECTAL CANCER, SUSCEPTIBILITY TO, 12 		0.100 GeneticVariation disease GWASCAT Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab. 30557370 2018
CUI: C0004096
Disease: Asthma
Asthma 		0.100 GeneticVariation disease GWASDB Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. 21804549 2011
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 AlteredExpression group BEFREE No significant association was determined between EphA5 expression and age, sex, primary location, depth of invasion and Tumor-Node-Metastasis stage. 31186729 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 Biomarker group BEFREE EPHA5 deficiency also caused significant aggrandized tumor malignancy in trastuzumab-sensitive xenografts, coinciding with the up-regulation of BCSC-related markers and intracellular Notch1 and PTEN/AKT signaling pathway activation. 30620624 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 AlteredExpression group BEFREE Expression of EphA5 was related negatively to Fuhrman grade (P = 0.013, r<sub>s </sub> = -0.279) and pathological tumour stage pT (P = 0.003, r<sub>s </sub> = -0.334). 28421649 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 Biomarker group BEFREE The loss of EphA5 protein was associated with depth of wall invasion (P=0.002), poor tumor differentiation (P<0.001), lymph node metastasis (P<0.001), and advanced TNM stage (P<0.001). 27651378 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.070 AlteredExpression group BEFREE In contrast, antiangiogenic and dormancy promoting pathways such as EphA5 and Angiomotin were upregulated in DmiR over-expressing tumors. 22952847 2012